BCIQ Profiles

Company Profile ReportTarget Profile Report

Replicor HBV combo leads to functional control

Replicor Inc. (Montreal, Quebec) reported interim data from the Moldovan Phase II REP 401 trial to treat chronic HBV infection showing that REP 2139-Mg in combination with Viread tenofovir disoproxil fumarate and Pegasys peginterferon

Read the full 345 word article

How to gain access

Continue reading with a
two-week free trial.